Will AstraZeneca Q1 results bring positive surprise?
Roland Magnusson/iStock Editorial via Getty Images

AstraZeneca (NASDAQ:AZN) is scheduled to announce Q1 earnings results on Thursday, April 27th, before market open.
The consensus EPS Estimate is $0.82 (-56.6% Y/Y) and the consensus Revenue Estimate is $10.61B (-6.8% Y/Y).
Over the last 2 years, AZN has beaten EPS estimates 88% of the time and has beaten revenue estimates 88% of the time.

Over the last 3 months, EPS estimates have seen 0 upward revisions and 1 downward. Revenue estimates have seen 0 upward revisions and 3 downward.

The British pharma giant's stock rose +4.75% on Feb. 9 following its Q4 results. Q4 saw a decline in sales of COVID vaccine Vaxzevria, but there was strong growth in Oncology, CVRM and Rare Disease segments.

Product/Pipeline updates:
AstraZeneca and Sanofi's RSV preventing therapy Beyfortus was approved in Canada for use in newborns.
Rare disease drug Ultomiris inched ahead on the path to get an expanded approval in the EU.
A combination treatment of Imfinzi and Lynparza improved progression-free survival in patients with a type of ovarian cancer in a phase 3 trial.